Evidence-based cardiology in hemodialysis patients

Journal of the American Society of Nephrology

Volumn 24, Issue 12, 2013, Pages 1934-1943

  Allon, Michael ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALBUMIN; ALDOSTERONE ANTAGONIST; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CARVEDILOL; CINACALCET; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRINOLYTIC AGENT; FOSINOPRIL; GLYCOSYLATED ALBUMIN; HEMOGLOBIN; HEMOGLOBIN A1C; HEPARIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE; PHOSPHATE BINDING AGENT; ROSUVASTATIN; SEVELAMER; SIMVASTATIN; UNINDEXED DRUG;

ANTICOAGULATION; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; LUNG EDEMA; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION; CARDIOVASCULAR DISEASES; KIDNEY FAILURE, CHRONIC; MORTALITY; PROCEDURES; RENAL REPLACEMENT THERAPY;

CARDIOLOGY; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 84889018563     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013060632     Document Type: Review

References (91)

1. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010-2019, 2002
2. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 [Suppl 3]: S112-S119, 1998
3. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka RJ, Kaufman AM, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS; HEMO StudyGroup:Cardiac diseases inmaintenance hemodialysis patients: Results of the HEMO Study. Kidney Int 65: 2380-2389, 2004
4. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE:Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 49: 1428-1434, 1996
5. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 47: 884-890, 1995
6. Genovesi S, Pogliani D, Faini A, Valsecchi MG, Riva A, Stefani F, Acquistapace I, Stella A, Bonforte G, DeVecchi A, DeCristofaro V, Buccianti G, Vincenti A: Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 46: 897-902, 2005
7. WinkelmayerWC, PatrickAR, Liu J, Brookhart MA, Setoguchi S: The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22: 349-357, 2011
8. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM: Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy. Kidney Int 77: 1098-1106, 2010
9. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS; FHN Trial Group: In-center hemodialysis six times per week versus three times perweek.NEnglJMed363: 2287-2300, 2010
10. Middleton RJ, Parfrey PS, Foley RN: Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 12: 1079-1084, 2001
11. Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
12. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, GoodmanWG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS; EVOLVE Trial Investigators: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367: 2482-2494, 2012
13. Palmer SC, Sciancalepore M, Strippoli GFM: Trial quality in nephrology: How are we measuring up?AmJ KidneyDis 58: 335-337, 2011
14. Greene T: Randomized and observational studies in nephrology: How strong is the evidence? Am J Kidney Dis 53: 377-388, 2009
15. Herzog CA: How tomanage the renal patient with coronary heart disease: The agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 14: 2556-2572, 2003
16. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr., Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Emergency PhysiciansSociety for Cardiovascular Angiography and Interventions: 2013 ACCF/AHA guideline for themanagement of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61: e78-e140, 2013
17. Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M: Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: A collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 116: 1465-1472, 2007
18. Best PJM, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB: The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39: 1113-1119, 2002
19. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315-1323, 2003
20. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M; BASKET-PROVE Study Group: Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 363: 2310-2319, 2010
21. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW: A pooled analysis of data comparing sirolimus-eluting stents with baremetal stents.NEngl J Med356: 989-997, 2007
22. Charytan DM, Varma MR, Silbaugh TS, Lovett AF, Normand SLT, Mauri L: Long-term clinical outcomes following drug-eluting or baremetal stent placement in patientswith severely reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. Am J Kidney Dis 57: 202-211, 2011
23. Chang TI, Shilane D, Kazi DS, Montez-Rath ME, Hlatky MA, Winkelmayer WC: Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol 23: 2042-2049, 2012
24. Grundy SM, Pasternak R, Greenland P, Smith SF Jr., Fuster V: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100: 1481-1492, 1999
25. Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, JamesM, Hemmelgarn B; Alberta Kidney Disease Network: Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol 24: 979-986, 2013
26. Agarwal R: The controversies of diagnosing and treating hypertension among hemodialysis patients. SeminDial 25: 370-376, 2012
27. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y; Osaka CKD Expert Research Group: Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: Effect of anemia and erythropoietin injection. J Am Soc Nephrol 18: 896-903, 2007
28. Freedman BI, Andries L, Shihabi ZK, Rocco MV, Byers JR, Cardona CY, Pickard MA, Henderson DL, Sadler MV, Courchene LM, Jordan JR, Balderston SS, Graham AD, Mauck VL, Russell GB, Bleyer AJ: Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 6: 1635-1643, 2011
29. Murea M, Moran T, Russell GB, Shihabi ZK, Byers JR, Andries L, Bleyer AJ, Freedman BI: Glycated albumin, not hemoglobin A1c, predicts cardiovascular hospitalization and length of stay in diabetic patients on dialysis. Am J Nephrol 36: 488-496, 2012
30. Mc Causland FR, Brunelli SM, Waikar SS: Association of smoking with cardiovascular and infection-related morbidity and mortality in chronic hemodialysis. Clin J Am Soc Nephrol 7: 1827-1835, 2012
31. Lam NN, Jain AK, Hackam DG, CuerdenMS, Suri RS, Huo CY, Li P, Clark WF, Garg AX: Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription. Kidney Int 76: 1172-1179, 2009
32. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G,McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
33. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J,Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B,Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, HoldaasH, Tesar V, Wiecek A, GrobbeeD, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, LewisD, Herrington W, MafhamM,Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, KnottC, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebocontrolled trial. Lancet 377: 2181-2192, 2011
34. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, Bloembergen WE, Greer JW, Hakim RM: The dose of hemodialysis and patient mortality. Kidney Int 50: 550-556, 1996
35. Owen WF Jr., Lew NL, Liu YL, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: 1001-1006, 1993
36. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA:Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 13: 1061-1066, 2002
37. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D: Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 55: 286-293, 1999
38. Port FK, Wolfe RA, Hulbert-Shearon TE, Daugirdas JT, Agodoa LY, Jones C, Orzol SM, Held PJ: Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: Results from the usrds dialysis morbidity and mortality study. Am J Kidney Dis 37: 276-286, 2001
39. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH,Czekalski S, RoncoC, Vanholder R; Membrane Permeability Outcome (MPO) Study Group: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 20: 645-654, 2009
40. Tattersall JE, Ward RA; EUDIAL group: Online haemodiafiltration: Definition, dose quantification and safety revisited. Nephrol Dial Transplant 28: 542-550, 2013
41. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, Soler J, Torres F, Campistol JM, Martinez-Castelao A; ESHOL Study Group: High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 24: 487-497, 2013
42. Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, Hur E, Demirci MS, Demirci C, Duman S, Basci A, Adam SM, Isik IO, Zengin M, Suleymanlar G, Yilmaz ME, Ozkahya M; Turkish Online Haemodiafiltration Study: Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: Results from the Turkish OL-HDF Study. Nephrol Dial Transplant 28: 192-202, 2013
43. Grooteman MPC, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AHA, den Hoedt CH, van der Tweel I, Lévesque R, Nubé MJ, ter Wee PM, Blankestijn PJ; CONTRAST Investigators: Effect of online hemodiafiltration on allcause mortality and cardiovascular outcomes. J Am SocNephrol 23: 1087-1096, 2012
44. Li S, Collins AJ: Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 65: 626-633, 2004
45. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
46. Coyne DW: The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 82: 235-241, 2012
47. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
48. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
49. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
50. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
51. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment ofChronic KidneyDisease-Mineral And Bone Disorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
52. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-441, 2007
53. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
54. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, BudoffM; CARE-2 Investigators: A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation- 2 (CARE-2) study. AmJ Kidney Dis 51: 952-965, 2008
55. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130-1137, 2007
56. SheminD, Lapane KL, Bausserman L, Kanaan E, Kahn S, Dworkin L, Bostom AG: Plasma total homocysteine and hemodialysis access thrombosis: A prospective study. J Am Soc Nephrol 10: 1095-1099, 1999
57. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP: Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 15: 420-426, 2004
58. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators: Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA 298: 1163-1170, 2007
59. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr.; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567-1577, 2006
60. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002
61. Galle J, Seibold S: Has the time come to use antioxidant therapy in uraemic patients? Nephrol Dial Transplant 18: 1452-1455, 2003
62. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 356: 1213-1218, 2000
63. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation 107: 992-995, 2003
64. The CONSENSUS Trial Study Group: Effects of enalapril onmortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial StudyGroup.NEngl J Med316: 1429-1435, 1987
65. CIBIS II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353: 9-13, 1999
66. MERIT-HF Study Group: Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001-2007, 1999
67. PackerM, BristowMR, Cohn JN,Colucci WS, Fowler MB, Gilbert EM, Shusterman NH; US Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349-1355, 1996
68. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J; Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity andmortality in patients with severe heart failure.NEnglJMed341: 709-717, 1999
69. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators: Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350: 2151-2158, 2004
70. Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A: Dilated cardiomyopathy in dialysis patients-beneficial effects of carvedilol: A double-blind, placebocontrolled trial. J AmColl Cardiol 37: 407-411, 2001
71. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE,Golino P, Calabrò R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo- controlled trial. J Am Coll Cardiol 41: 1438-1444, 2003
72. Charytan DM, Patrick AR, Liu J, Setoguchi S, Herzog CA, Brookhart MA, Winkelmayer WC: Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 58: 409-417, 2011
73. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285: 2370-2375, 2001
74. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 285: 2864-2870, 2001
75. Hart RG, Pearce LA, Aguilar MI:Meta-analysis: Antithrombotic therapy to prevent stroke in patientswho have nonvalvular atrial fibrillation. Ann Intern Med 146: 857-867, 2007
76. vanWalraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B: Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 288: 2441-2448, 2002
77. Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, ValsecchiMG: Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 51: 255-262, 2008
78. Chan KE, Lazarus JM, Thadhani R, HakimRM: Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20: 2223-2233, 2009
79. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, BordenWB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D,MarcusGM,Marelli A,Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS,Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 127: e6-e245, 2013
80. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK: Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 6: 2662-2668, 2011
81. Olesen JB, Lip GYH, Kamper AL, Hommel K, Køber L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C: Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367: 625-635, 2012
82. Limdi NA, Beasley TM, Baird MF, Goldstein JA,McGwinG, ArnettDK, Acton RT, AllonM: Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 20: 912-921, 2009
83. Wieloch M, Jönsson KM, Själander A, Lip GYH, Eriksson N, Svensson PJ: Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin. Thromb Res 131: 481-486, 2013
84. Ahmad Y, Lip GY: Preventing stroke and systemic embolism in renal patients with atrial fibrillation: Focus on anticoagulation. Contrib Nephrol 179: 81-91, 2013
85. Krüger T, Brandenburg VM, Schlieper G, MarxN, Floege J: Sailing between Scylla and Charybdis: Oral long-termanticoagulation in dialysis patients.Nephrol Dial Transplant 28: 534-541, 2013
86. Krane V, Heinrich F,Meesmann M, Olschewski M, Lilienthal J, Angermann C, Störk S, Bauersachs J, Wanner C, Frantz S; German Diabetes and Dialysis Study Investigators: Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clin JAmSocNephrol 4: 394-400, 2009
87. LondonGM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 12: 2759-2767, 2001
88. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J AmSoc Nephrol 16: 2180-2189, 2005
89. Foley RN, Parfrey PS, Morgan J, Barré PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A,Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325-1335, 2000
90. Zannad F, Kessler M, Lehert P, Grünfeld JP, Thuilliez C, Leizorovicz A, Lechat P: Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70: 1318-1324, 2006
91. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, Manns BJ: Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: A randomized controlled trial. JAMA 298: 1291-1299, 2007